Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.

Introduction: Patients undergoing CAR T-cell therapy may experience severe cytopenias due to lymphodepleting chemotherapy and/or T-cells. Transfusion needs represent a surrogate marker of anemia and thrombocytopenia. impact patients’ quality life T-cells efficacy through transfusion-related immunomodulation. Here, we aimed describe transfusion patients receiving commercial CD19 for relapse or refractory large B-cell lymphoma (LBCL), identify predictive factors associated with transfusions search correlations efficacy. Methods: Clinical data were collected form the DESCAR-T registry, French national real-life registry all treated from blood bank. We included LBCL at least 6-months follow-up infusion. censored relapse, new treatment onset, death. Results: From August 2018 September 2022, 671 in met eligibility criteria. Overall, 382 (56.9%) received one after infusion: 53.5% early phase (i.e. within first month), 37.8% late beyond month). Only 6% required 3 months. The mean number red cells (RBC) units platelets per patient 3.5 (range, 0–90) 5.1 0–127), respectively. Factors are presented Table 1. Age, international prognostic index, primary status, prior ASCT, bulk disease, cytokine release syndrome (CRS) but not RBC transfusions. Early shared same risk except CRS. No association was found between response rate therapy. However, (RBC platelets) shorter progression-free survival (median PFS = 3.2 vs. 6.0 months, p 0.0168) overall OS 9.3 23.6 < .0001). Late decreased 5.6 12.0 0.0072) 13.8 NR, .0001) whereas did nor OS. Conclusion: In our study, 56.9% identified needs. worse survival. Our shed light on mechanisms thrombocytopenia, potential Encore Abstract - previously submitted EHA 2023 Keywords: Aggressive non-Hodgkin lymphoma, Cellular therapies Conflicts interests pertinent abstract. E. Bachy Honoraria: Kite, Gilead Company, Bristol Myers Squibb, Novartis, Pfizer, Incyte, ADC Therapeutics Research funding: Amgen, BMS Other remuneration: Pfizer G. Cartron Consultant advisory role: Roche, Celgene-BMS, Onwards Therapeutics, MedxCell, EmerCell, MabQi Sanofi, Abbvie, Takeda, Janssen, Celgene, Incyte Consulting fees Roche Celgene-BMS T. Gastinne Sciences Educational grants: F. Morschhauser Novartis K. Bouabdallah Kite/Gilead, Takeda Kite/Gilead O. Casasnovas ROCHE, TAKEDA, GLIEAD/KITE, MSD, GILEAD/KITE, BMS, AMGEN, ABBVIE, JANSSEN GILEAD/KITE (research funding institution) S. Choquet Kite C. Castilla-Llorente Gilead/Kite Guidez Gilead, M. Loschi Alexion, Iqone, Sanofi Sobi L. Drieu La Rochelle Gilead/kite R. Houot Bristol-Myers Squibb/Celgene, Miltenyi